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Abstract 
Insulinoma is the most frequently encountered functioning endocrine pancreatic tumor 
in humans. In this overview we summarize morphological and clinical features of 
insulinomas, report about the proinsulin-insulin conversion in normal and neoplastic B- 
cells, discuss the new classification, the criteria of malignancy, and the clonal composition 
of endocrine pancreatic tumors, and outline recent findings on the molecular pathology 
of these tumors. 
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Introduction 
Endocrine pancreatic tumors (EPTs) 
have a prevalence ofapprox 1 in a popula- 
tion of 100,000 and an incidence of 1 per 
106 per year for insulinomas and gastrino- 
mas, and one of 1 per 107 per year for the 
other tumors. 
EPTs giving rise to well-deflned hor- 
monal syndromes are designated "function- 
ing" and are classified according to the 
hormone responsible for the clinical syn- 
drome. "Nonfunctioning" (nonsecreting, 
inactive, hormonally silent) EPTs do not 
lead to endocrinological symptoms and 
may be named according to the major 
product detected by immunohistochemis- 
try or radioimmunoassay, i.e., "EPT with 
production of insulin." 
In surgical series, functioning EPTs 
account for 60-85% of all EPTs [1]. Clin- 
ically unrecognized and asymptomatic 
tumors, usually smaller than 1 cm in 
diameter, are found in 0.4-1.5% of unse- 
lected autopsies [2]. In surgical series, 
nonfunctioning tumors comprise 15-21% 
of all EPTs [1]; in our series of 501 tumors, 
it is the largest group representing 34% of 
all EPTs [3]. Approximately 25% of all 
EPTs are associated with multiple endo- 
crine neoplasia type 1 (MEN1). 
Mthough previously thought o arise 
from neural ectoderm, the neuroendocrine 
cells of the gastrointestinal system, includ- 
ing the pancreas, are derived from endo- 
derm [4,5]. However, whether EPTs 
originate from the ductular epithelium or 
the islet cells of the pancreas i still a mat- 
ter of debate [6]. 
Precise classification of EPTs requires 
analysis of the cell phenotype by immu- 
nohistochemistry (Tables 1 and 2). Because 
the tumors originate from cells that are 
"phenotypically" neuroendocrine, they 
share broad spectrum arkers for neuroen- 
docrine differentiation, such as neuron-spe- 
cific-enolase (NSE), synaptophysin, and 
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chromogranin A. In the majority of func- 
tioning tumors, the hormone causing the 
syndrome can be detected by immunohis- 
tochemistry at the light and electron 
microscopic level. Staining intensity or num- 
ber of positive cells, however, are not related 
to the severity of symptoms. Using a panel 
of antibodies against pancreatic hormones, 
many tumors turn out to be multihormonal. 
Nonfunctioning tumors frequently exhibit 
positivity for a variety of hormones, with- 
out causing clinical symptoms. 
Clinical Features of lnsulinomas 
Symptoms of hypoglycemia due to 
hypersecretion of insulin were first 
described by Harris in 1924 [7], and three 
years later the association between insulin- 
secreting EPTs and hypoglycemia w s rec- 
ognized by Wilder et al. [8]. 
Insulinomas re by far the most frequent 
of all functioning EPTs (prevalence: 1-1.25 
per 10 6 of people; incidence: four patients 
per 106 person years) [9,10]. Insulinomas 
have been diagnosed in all age groups, but 
rarely occur in adolescence. The highest 
incidence is found between 40 and 60 yr, 
with an average age of 44-46 yr. Approxi- 
mately 10% of the patients are younger 
than age 20 and 10% older than 60. There 
is 60:40 ratio of females to males in most 
reported series [1]. 
It is generally accepted that the vast 
majority of insulinomas are benign. The 
percentages of malignant tumors range 
from 2.4 to 17.9%, with an average of 
8.4% [10-14]. Malignant insulinomas 
occur in an older age group and have not 
been reported in children [15]. It appears 
that males are more frequently affected 
than females [16]. 
Virtually all functioning insulinomas 
manifest with symptoms of hypoglycemia, 
which include adrenergic and hypo-gly- 
copenic signs [17]. A gradual onset of 
sweating and palpitations (warning symp- 
toms) in hypoglycemia s typical. More 
than 80% of patients have transient symp- 
toms of CNS dysfunction, ranging from 
drowsiness to coma and epilepsia, nd there 
are several reports of insulinoma patients 
with erroneous psychiatric or neurologic 
diagnoses [ 13]. 
The diagnosis of an insulinoma is mainly 
based on laboratory examinations and pro- 
vocative tests. Inappropriate insulin values 
in relationship to the plasma glucose level 
are key characteristics ofhyperinsulinemic 
hypoglycemia due to an insulinoma. In 
healthy individuals the plasma insulin is 
suppressed to less than 6 gU/mL during 
hypoglycemia (<40 mg/dL; 2.2 mM) and 
the ratio of glucose to insulin is greater than 
2.5. The measurement of plasma proinsu- 
lin can also be helpful in the diagnosis 
ofinsulinoma. The majority of patients 
present proinsulin levels of more than 22% 
of the total plasma insulin, and it has been 
shown that especially malignant tumors 
present high plasma proinsulin levels 
[18,19]. 
Provocative t sts include monitored fast- 
ing and secretagogue stimulation of insu- 
lin by tolbutamide, glucagon, or calcium. 
The demonstration f low plasma glucose, 
and elevated or normal insulin in the 
absence of ketonuria suggests an insu- 
Iinoma. Insulinoma patients typically dem- 
onstrate unchanged C-peptide levels, 
owing to continuous insulin secretion by 
the tumor [20]. 
Methods of localizing insulinomas 
include noninvasive techniques such as 
ultrasonography, bolus-enhanced com- 
puted tomography (CT), magnetic reso- 
nance imaging, and octreotide scan, as well 
as invasive techniques such as arteriogra- 
phy with or without substraction and 
transhepatic portal venous ampling. 
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Table 1. Classification of EPT 
1. Well-differentiated endocrine tumor 
1.1. Functioning 
Insulin-producing (insulinoma) 
Glucagon-producing (glucagonoma) 
Somatostatin-producing (somatostatinoma) 
Gastrin-producing (gastrinoma) 
VIP-producing (vipoma) 
Serotonin producing tumor with carcinoid syndrome 
Others 
1.2. Nonfunctioning 
Microadenoma (<0,5 cm) 
Others 
2.Well-differentiated endocrine carcinoma 
2.1. Functioning (see 1.1. for types) 
2.2. Nonfunctioning 
3. Poorly differentiated endocrine carcinoma 
4. Mixed exocrine-endocrine tumor 
5. Tumor-like lesions 
Islet hyperplasia 
Nesidioblastosis 
Endocrine dysplasia 
Table 2. Clinicopathologic Correlations 
1. Well-differentiated endocrine tumor 
benign behavior: confined to the pancreas, 
nonangioinvasive, < 2 cm in sizd 
Functioning 
Insulinoma 
Non functioning 
uncertain behavior, confined to the pancreas; _> 2 cm in size or angioinvasive 
Functioning 
Gastrinoma, insulinoma, vipoma, glucagonoma, 
somatostatinoma or inappropriate syndrome" tumor 
Nonfunctioning 
2.Well-differentiated endocrine carcinoma 
low grade malignant with gross local invasion and/or metastases 
Functioning 
Gastrinoma, insulinoma, glucagonoma, vipoma, 
somatostatinoma or inappropriate syndrome'* tumor 
Non functioning 
3. Poorly differentiated endocrine carcinoma 
high grade malignant (small to intermediate cell) carcinoma 
"< 2 cm in size implies near 100% probability of benign behavior; < 3 cm corresponds to 90% probability. 
~" Inappropriate hormone syndromes: Cushing (ACTH), acromegaly orgigantism (GRH), hypercalcemia, and so on. 
Strategies for insulinoma treatment 
include surgical removal or debulking of 
tumor tissue, including liver transplanta- 
tion in case of metastases [21], drug therapy 
aimed at palliation of symptoms referable 
to hypoglycemia [22], and chemotherapy 
in patients with metastatic disease [23]. 
About two-thirds of the patients can be 
cured by resection of the tumor. Blind 
distal pancreas resection is indicated in 
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patients where the tumor cannot be located 
during operation and measurement of
changes in plasma glucose during surgery 
is a helpful means in predicting a cure for 
the patient [24]. 
(Histo)pathological Features 
of Insulinomas 
The majority ofinsulinomas occur in the 
pancreas orare attached toit. Extrapancreatic 
tumors are extremely rare (1.8%) and are 
most commonly found in the duodenal 
wall [25,26].. Macroscopically insulinomas 
are usually red-brown in color and are 
softer than the surrounding pancreatic tis- 
sue, with the exception of tumors with a 
large amount of fibrous stroma and/or 
amyloid. Collective data indicate that 
tumors are equally distributed between the 
head, body, and tail of the pancreas with a 
slight predominance of the head and tail 
region [25-28]; 83% ofinsulinomas occur 
single, 11-13% multiple, and 4% are 
associated with MEN 1 [29]. Functioning 
insulinomas re frequently discovered while 
still small and the reported mean size of the 
tumors has varied from microscopic up to 
11 cm: 75% of the tumors are between 0.5- 
2 cm and weigh less than 2 g. Symptoms of 
hypoglycemia are unrelated to the size of 
tumor [18]. Only 8% of tumors are larger 
than 5 cm [25]. These tumors are more 
likely to be malignant than smaller ones. 
The insulinomas producing a hypogly- 
cemic syndrome in MEN1 patients are 
usually larger than 1 cm, and microade- 
nomas with insulin expression, o matter 
how numerous they are, seem to remain 
functionally silent. This implies that the 
insulinomas inMEN 1 patients are among 
the grossly apparent and palpable pancre- 
atic tumors. If there are several large tumors, 
usually only one of them is an insulinoma. 
Multiple large insulinomas re rare. 
Several histological c assifications have 
been proposed for sporadic insulinomas 
[30-32]. However, the clinical relevance 
of such classifications is not proven. Most 
insulinomas store insulin and proinsulin in 
a sufficient amount to be easily visualized 
by immunohistochemistry. Typically insu- 
lin-rich cells account for 60-80% of all 
tumor cells. However, the amount of 
immunohistochemical presence of insulin 
does not correlate with hormone levels in 
the serum. About half of the insulinomas 
are multihormonal. In such tumors insu- 
lin-rich cells are admixed with cells 
producing lucagon, somatostatin, or
pancreatic polypeptide. Amyloid deposi- 
tion is a common finding in insulinomas 
and immunohistochemical detection of 
islet amyloid polypeptide (IAPP) or 
amylin, apossible causative factor for amy- 
loid deposition, has recently been described 
in 16 out of 19 tumors [33]. 
Proinsulin-lnsulin Conversion 
in Insulinomas 
The biosynthesis of insulin commences 
in the endoplasmic reticulum (ER), and the 
preproinsulin becomes converted to pro- 
insulin in the ER by the action of a signal 
peptidase. This is followed by various post- 
translational processing steps involving the 
action of two prohormone-converting 
endoproteases and of carboxypeptidase H. 
Each of the two endoproteases preferen- 
tially cleaves one of the two dibasic leav- 
age sites in proinsulin, followed by the 
removal of the C-terminal basic residue by 
carboxypeptidase H. Thus, two cycles of 
combined endoprotease-carboxypeptidase 
action are required to generate mature 
insulin and C-peptide from proinsulin. 
These processing steps are accompanied by
the sorting and packing of insulin into 
secretory granules. The combination of 
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biochemical and immunohistochemical 
approaches has permitted the fine analysis 
of the proinsulin-insulin conversion in 
normal pancreatic beta cells [3]. In light 
microscopic studies, the proinsulin-specific 
monoclonal antibody GS-9 A 8, recog- 
nizing an epitope around the dibasic pro- 
cessing site Arg31-Arg32, resulted in a 
Golgi-like staining pattern (Fig. 1). By 
immunoelectron microscopy, this antibody 
provided in situ evidence that the proinsu- 
lin-insulin conversion takes place in par- 
tially clathrin-coated, acidic immature 
secretory granules. Subsequent immuno- 
electron microscopic studies provided evi- 
dence that the endoproteolytic cleavage at 
the dibasic pair Lys64-Arg65 in the A 
chain/C-peptide junction also occurred in 
the clathrin-coated immature secretory 
granules. These data were complemented 
by microscopic studies, applying a mon- 
odonal antibody specific for insulin. By 
light microscopy, adiffuse cytoplasmic la- 
beling for insulin was evident (Fig. 1). By 
immunoelectron microscopy, insulin 
immunolabeling first became detectable in
clathrin-coated immature secretory gran- 
ules, which upon acidification transformed 
in mature secretory granules and exhibited 
highest labeling for insulin. Thus, in nor- 
mal pancreatic beta cells, proinsulin-insu- 
lin conversion occurs in acidic immature 
secretory granules of the trans Golgi appa- 
ratus (Fig. 2). 
Insulinomas can exhibit many structural 
and immunohistochemical features, in 
common with normal beta cells. However, 
even within a given insulinoma, insulin 
immunostaining and ultrastructural details 
of secretory granule morphology may vary 
greatly. Variability is also observed in their 
clinical manifestations. We have investi- 
gated the distribution pattern of proinsu- 
lin and insulin by light and electron 
microscopic mmunolabeling, applying the 
proinsulin and insulin-specific monoclonal 
antibodies [34,35]. By light microscopy, 76 
human insulinomas were studied. One tra- 
becular and two solid insulinomas showed 
the staining patterns of normal beta cells. 
A "near normal" staining pattern, peri- 
nuclear proinsulin and diffuse or polarized 
insulin staining (Fig. 1), existed in 10/27 
trabecular and 11/44 solid insulinomas. An 
"intermediate" staining pattern, intense 
perinuclear s well as weaker diffuse pro- 
insulin staining with diffuse or polarized 
insulin staining (Fig. 1) was observed in 
10/27 trabecular and 20/44 solid insuli- 
nomas. Of the five glandular insulinomas, 
four exhibited a "near normal" and one an 
"abnormal" staining pattern. Similar esults 
were obtained by others in a recent immu- 
nohistochemical study [36], which also 
addressed the immunohistochemistry of 
the prohormone processing enzymes. In 
our studies, no correlation was found 
among any particular staining pattern, his- 
tological type, the multihormonali~ or the 
malignancy of the insulinomas [35]. The 
abnormal labeling pattern for proinsulin 
in about 60% of the insulinomas was sug- 
gestive of topographical bnormalities of
hormone conversion and an immuno- 
electron microscopic study was carried out 
in seven such insulinomas [34]. We found 
that, in contrast to normal beta cells, the 
proinsulin-insulin conversion i  insulinomas 
occurred already in the Golgi apparatus 
(Fig. 3), but remained incomplete, result- 
ing in the formation of secretory granules 
containing both proinsulin and insulin 
(Figs. 2 and 3). This indicates that in insu- 
linoma sorting into secretory granules may 
not be a prerequisite for hormone conver- 
sion. It also indicates that proinsulin and 
insulin storage and secretion occur through 
secretory granules via the regulated secre- 
tory pathway. A substantial variability for 
both proinsulin and insulin immunola- 
beling in secretory granules was observed 
not only in individual tumor cells, but also 
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Fig. 1. Immunohistochemical detection of proinsulin (A, C, E) and insulin (B, D, F) in human pancreas 
and insulinomas, paraffin sections, silver-intensified immunogold staining using monoclonal antibod- 
ies specific for proinsulin and insulin. In islets of Langerhans of normal human pancreas, proinsulin 
immunohistochemistry results in a perinuclear crescent-shaped, Golgi staining pattern (A). Insulin 
immunostaining in a serial section consecutive to the one shown in (A) results in a diffuse cytoplasmic 
labeling (B). Insulinomas may exhibit a near normal perinuclear proinsulin staining (C) and a polarized 
cytoplasmic insulin staining (D). However, insulinomas may show an abnormal diffuse proinsulin staining 
pattern (E). Insulin immunostaining in a consecutive serial section from the insulinoma shown in (E) is 
presened in (F). 
among the insulinomas studied. This vari- 
ability may account for the lack of correla- 
tion between pathohistological, immuno- 
histochemical, nd clinical parameters in 
functioning insulinomas [34-36]. 
Criteria of Malignancy in EPTs 
Based on the work ofCapella et al. [37], 
the World Health Organization (WHO) 
has elaborated a new classification fneu- 
roendocrine tumors including EPTs, 
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Fig. 2. Schematic presentation of proinsulin-insulin conversion i  normal pancre- 
atic beta cells (A) and human insulinoma (B). For details, ee text. 
which is currently in press and has been 
presented in review articles [38,39]. In the 
new classification (Table 1), tumors maller 
than 2 cm in size, confined to the pancreas, 
without angio-invasion or metastases and 
with a mitotic rate of less than 2 mitoses 
per 10 high power fields or less than 2% Ki 
67 (or MiB-1) staining index are considered 
benign. However, the only reliable criteria 
for malignancy are the infiltration of the 
tumor into adjacent organs (e.g., the 
spleen), the presence of angioinvasion of 
lymph node, and/or distant metastases [40]. 
It has been hypothesized that immuno- 
histochemical markers might be helpful in 
identifying tumors with a more aggressive 
Fig. 3. Immunoelectron microscopic demonstration of proinsulin and insulin in a human 
insulinoma, immunogold labeling, Lowicryl K4M thin sections. Insulin immunoreactivity as indi- 
cated by the electron dense gold particles is present over the Golgi apparatus (G)and electron 
dense core secretory granules (A}, Immunogold labeling for proinsulin can be found also in 
secretory granules in the periphery of the insulinoma cells (B). 
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biological behavior or the potential for 
metastatic disease. However, most of the 
proposed markers have been shown to be 
only of limited value in the daily practice 
[41] and the individual prognosis of a given 
patient with an EPT cannot be satisfac- 
torily predicted by conventional histologi- 
cal parameters or immunohistochemical 
expression patterns. 
Thus, in a study on 53 EPTs (38 benign, 
15 malignant) we could demonstrate hat 
the expression of polysialylated NCAM, 
NCAM protein isoforms, and beta-l,6- 
branched, asparagine-linked oligosac- 
charides, which have been associated with 
increased aggressiveness, metastatic poten- 
tial, and survival in other tumor types [42], 
are not suitable to distinguish between 
malignant and benign EPTs. Polysialylated 
NCAM was not detectable in benign and 
malignant insulinomas, and the NCAM 
protein isoform pattern was similar as well. 
Furthermore, 11/15 (74%) of the malig- 
nant and 23/38 (63%) of the benign 
tumors exhibited staining for beta-l,6- 
branches [43]. In another study on 134 
neuroendocrine tumors of different 
locations, including 27 EPTs (6 insu- 
linomas, 10 gastrinomas, 1 glucagonoma, 
3 somatostatinomas, 7 VlPomas), we could 
demonstrate that not only gastrinomas nd 
nonfunctioning EPTs (as reported by other 
groups) but also other types of EPTs may 
express the glycoprotein CD44 and its 
isoforms and that the expression of CD44 
is not associated with a malignant pheno- 
type or tumor progression as reported for 
other types of human tumors [44]. 
Clonal Composition of EPTs 
In a study on the clonality of 34 malig- 
nant and benign EPTs of different ypes 
from female patients [44], we have shown 
that 7/20 of the informative tumors 
exhibited a monoclonal (35%), 10/20 a 
polyclonal, 1/20 an oligoclonal pattern, 
and 2/20 a loss of heterozygosity (LOH) 
at the Xql2-1ocus. When comparing be- 
nign and malignant neoplasms, benign 
tumors more often exhibited apolyclonal 
(5/7) pattern, while malignant umors 
more frequently showed a monoClonal 
(8/13), an oligoclonal (1/20) pattern, or 
LOH (2/20). These results are consistent 
with the hypothesis that EPTs might pri- 
marily be polyclonal or oligoclonal neo- 
plasms, which are eventually outgrown by 
a more aggressive cell clone that gives rise 
to invasive growth and/or metastasis. Fur- 
thermore, we postulated that the X-chro- 
mosome, which was lost in two of the 
examined highly malignant EPTs, might 
play a role in the progression of EPTs by 
inactivation of a not yet identified tumor 
suppressor gene [45]. 
Molecular Pathogenesis of EPTs 
Although the molecular basis of the 
familial EPTs (which are associated with 
MEN1 and VHL) has recently been 
established [46,47], only little is known 
about the oncogenesis and the molecular 
basis of progression of sporadically occur- 
ring EPTs. A small number of published 
studies indicate that in contrast o other 
human tumors, the activation ofoncogenes 
is not an early event in EPTs. It was shown 
that, for example, the protein- and RNA- 
expression (but not mutations) of H-ras 
and K-ras is associated with the progres- 
sion of sporadic EPTs and oncogenes (such 
asj~s, c-rnyc, M-rnyc, and sis) or tumor sup- 
pressor genes (such as p53 and Rb), which 
are frequently mutated or activated in other 
human tumors, appear not to be involved 
in the neoplastic transformation fEPTs, 
or merely involved as a late event [48-51]. 
Furthermore, in an analysis of 112 spo- 
radic neuroendocrine tumors for PET- 
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protooncogene mutations, we found that 
the 17 examined EPTs lacked mutations 
in all five examined RET-protooncogene 
exons, which indicates that this gene is not 
generally important in the tumorigenesis 
of EPTs [52]. 
Molecular and cytogenetic analysis have 
led to the identification of a number of 
chromosomal lterations in EPTs. How- 
ever, no consistent pattern has been noted 
so far. There are indications that certain 
chromosomal bnormalities are more fre- 
quently encountered in EPTs. 
Several LOH studies have shown that 
the chromosome 1 lq13 region is deleted 
in a subset of EPTs [51,53]. The chromo- 
somal region l lq13 is the locus of the 
recently identified MEN1 gene. Thus, it is 
tempting to assume that MEN1 mutations 
are also involved in the formation of 
sporadic EPTs. However, we and others 
[53-55] could only identify a small per- 
centage of sporadic EPTs harboring 
somatic mutations in the MEN1 gene, 
indicating that this gene is only involved 
in a subset of EPTs and that the majority 
of EPTs are probably caused by other 
genetic lesions. In the study of Zhuang et 
al. on 12 sporadic insulinomas, only two 
tumors exhibited an inactivating MEN1 
gene mutation [53] and in our own series 
of 30 EPTs we have observed a mutation 
rate of only 4/30 (13.3%). The series also 
included nine insulinomas, which exhib- 
ited frequencies of 44.4% for LOH (4/9) 
and 11.1% for mutations (1/9) [54-56]. 
LOH studies on other loci did not reveal 
any other concise candidate gene for the 
initiation or progression of sporadic EPTs 
[50,51,57]. For example, it recently has 
been demonstrated that loss of chromo- 
some 3p25 in sporadic EPTs is associated 
with a more aggressive phenotype [58] and 
that no mutations of the VHL gene (which 
is located in this particular egion of the 
chromosome) is present in these tumors 
[58]. Further chromosomal loci that have 
been occasionally found deleted in sporadic 
EPTs include chromosome lp, 5q, 9q, 7q, 
and 16q [60,61]. 
Only a few publications exist on cyto- 
genetic aberrations in EPTs [62,63]. They 
were mainly observed in cultured tumor 
cells and the identified changes were not 
confirmed by LOH or FISH methods. One 
study on cultured EPTs of nine patients 
showed a multitude of chromosomal 
aberrations in half of the investigated 
tumors. However, no consistent aberration 
has been noted and cytogenetical findings 
were not correlated with clinical data [63]. 
Another recently published study on 16 
insulinomas from transgenic mice (with a 
SV40-1arge-T-antigen transgene under the 
control of the rat insulin promoter) 
reported LOH on the mouse chromosomes 
9 and 16, which are homologous to the 
human chromosome regions 6p, 3p, 3q 
and 22q, 21q, 3q, respectively, in a major- 
ity of examined tumors [61]. In the same 
study, additional losses on chromosomes 
2, 6, 7, 11, 13, and 14 could be identified 
using comparative genomic hybridization 
(CGH). In our own CGH study, we have 
analyzed 44 benign and malignant EPTs, 
in order to correlate the overall number of 
genetic alterations with clinical and histo- 
pathological parameters and to identify 
chromosomal regions that might harbor 
genes involved in EPT initiation and pro- 
gression. Aberrations were found in 36 
EPTs and chromosomal losses were slightly 
more frequent han gains. The most fre- 
quent losses involved Y, 6q, 11 q, 3p, 3q, 
1 lp, 6p, 10q, and Xq, and most common 
gains included 7q, 17q, 5q, 14q, 7p, 9q, 
17p, 20q, 12q, and Xp. A correlation was 
found between the total number of genetic 
changes per tumor and both tumor size and 
disease stage. In particular, losses of 3p and 
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6q and gains of 14q and Xq were found to 
be associated with metastatic disease. Fur- 
thermore, characteristic patterns of genetic 
changes were found in the various EPT 
subtypes, e.g., 6q loss in malignant insu- 
linomas, indicating that hese groups might 
evolve along enetically different pathways. 
The highlighted genetic aberrations, 
including the newly found involvement of
6q losses and sex chromosome alterations, 
should stimulate the further analysis of 
these chromosomal regions, which may 
lead to the discovery of novel genes impor- 
tant in the tumorigenesis and evolution of 
EPTs [64,65]. 
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